IP Library › Granted Patent US 12,653,890
Granted Patent B2
US 12,653,890 · App. 18/510,716 · Granted Jun 16, 2026

Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Inventors: Elsa Borghi (Saint-Remy-les-Chevreuse, FR); Laurent Levy (Paris, FR); Agnès Pottier (Paris, FR)
Assignee: NANOBIOTIX S.A.
A61K41/0038A61K9/14B82Y5/00A61N2005/1087A61N2005/1089A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,890
App. No.
18/510,716
Granted
Jun 16, 2026
Kind
B2
Abstract

The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Claims (14)

1 . A method for treating solid tumor cancer comprising administering to a human subject suffering from the solid tumor cancer by intra-tumoral injection a composition comprising a suspension of inorganic nanoparticles, determining the tumor volume, determining the volume of the composition comprising the inorganic nanoparticles within the tumor volume by radiography or computed tomography, and exposing the tumor of the human subject to ionizing radiation, wherein the inorganic nanoparticles provide more than 7×10 22 electrons to the tumor, the inorganic material constituting the nanoparticles has a theoretical (bulk) density of at least 7 and an effective atomic number (Z eff ) of at least 25, and the volume of the composition (Vc) occupies between 2% and 55% of the tumor volume.

2 . The method according to claim 1 , wherein said ionizing radiation is selected from X-rays, ion beams, electron beams, gamma-rays, or a radioactive isotope.

3 . The method according to claim 1 , wherein said composition has a volume that is between 2% and 45% of the tumor volume.

4 . The method according to claim 1 , wherein the inorganic material constituting the nanoparticles is selected from an oxide, a metal, a sulfide and any mixture thereof.

5 . The method according to claim 4 , wherein the inorganic material constituting the nanoparticles is a metal oxide and is selected from Cerium (IV) oxide (CeO 2 ), Neodymium (III) oxide (Nd 2 O 3 ), Samarium (III) oxide (Sm 2 O 3 ), Europium (III) oxide (Eu 2 O 3 ), Gadolinium (III) oxide (Gd 2 O 3 ), Terbium (III) oxide (Tb 2 O 3 ), Dysprosium (III) oxide (Dy 2 O 3 ), Holmium oxide (Ho 2 O 3 ), Erbium oxide (Er 2 O 3 ), Thulium (III) oxide (Tm 2 O 3 ), Ytterbium oxide (Yb 2 O 3 ), Lutetium oxide (Lu 2 O 3 ), Hafnium (IV) oxide (HfO 2 ), Tantalum (V) oxide (Ta 2 O 5 ), Rhenium (IV) oxide (ReO 2 ), and Bismuth (III) oxide (Bi 2 O 3 ) and any mixture thereof.

6 . The method according to claim 4 , wherein the inorganic material constituting the nanoparticles is a metal selected from gold (Au), silver (Ag), platinum (Pt), palladium (Pd), tin (Sn), tantalum (Ta), ytterbium (Yb), zirconium (Zr), hafnium (HI), terbium (Tb), thulium (Tm), cerium (Ce), dysprosium (Dy), erbium (Er), europium (Eu), holmium (Ho), iron (Fe), lanthanum (La), neodymium (Nd), praseodymium (Pr), lutetium (Lu) and any mixture thereof.

7 . The method according to claim 4 , wherein the inorganic material is selected from a hafnium oxide, rhenium oxide, europium oxide, a mixture of zirconium and of an inorganic oxide, and any mixture thereof.

8 . The method according to claim 1 , wherein the inorganic nanoparticles comprise a mixture of an inorganic oxide and of a metal.

9 . The method according to claim 1 , wherein the largest dimension of a nanoparticle is between about 5 nm and about 250 nm.

10 . The method according to claim 1 , said method comprising determining the electron density of the volume of the composition comprising the inorganic nanoparticles (Vc) and administering to the human subject a volume of the inorganic nanoparticles that occupies between 2.5% and 50% of the tumor volume.

11 . The method according to claim 1 , wherein the method comprises a step of calculating the quantity of electrons provided by the inorganic nanoparticles to the tumor using the following formula:

Quantity of electrons= V NP (cm 3 )×ρ e − material ,

with ρ e − material =d material ×e − material and V NP (cm3)=X mean ×Vc (cm 3 )/d material (g/cm 3 )/1000 (cm 3 ), wherein d material is the theoretical (bulk) density of material constituting the inorganic nanoparticles, e − material is the number of electrons per gram of the material constituting the inorganic nanoparticles, Vc represents volume composition and corresponds to the volume of the suspension of inorganic nanoparticles which is administered to the subject, and X mean corresponds to the concentration of the inorganic nanoparticle suspension which is injected into the tumor.

12 . The method according to claim 11 , wherein the inorganic nanoparticles comprise an inorganic material that has an effective atomic number (Z eff ) of at least 40.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2023
From: BORGHI, ELSA; LEVY, LAURENT; POTTIER, AGNÈS
To: NANOBIOTIX S.A.
Reel/Frame 065589/0353 →
Priority Claims (1)
EP 13305087 · Jan 25, 2013 · regional
Continuity (5)
Continuation 17331674 · May 27, 2021
Continuation 16129851 · Sep 13, 2018
Continuation 14762971
Provisional Application 61756533 · Jan 25, 2013
Related Publication 20240100163A1 · Mar 28, 2024
References Cited (52)
US 7367934B2 · Hainfeld et al. · 2008 [cited by applicant]
US 9700621B2 · Levy et al. · 2017 [cited by applicant]
US 9956175B2 · Pottier et al. · 2018 [cited by applicant]
US 10064962B2 · Pottier et al. · 2018 [cited by applicant]
US 10098952B2 · Borghi et al. · 2018 [cited by applicant]
US 10265406B2 · Pottier et al. · 2019 [cited by applicant]
US 10391058B2 · Germain et al. · 2019 [cited by applicant]
US 10391174B2 · Levy et al. · 2019 [cited by applicant]
US 10413509B2 · Pottier et al. · 2019 [cited by applicant]
US 10588987B2 · Poul et al. · 2020 [cited by applicant]
US 10765632B2 · Germain et al. · 2020 [cited by applicant]
US 10945965B2 · Pottier et al. · 2021 [cited by applicant]
US 11020480B2 · Borghi et al. · 2021 [cited by applicant]
US 11096962B2 · Marill et al. · 2021 [cited by applicant]
US 11191846B2 · Meyre et al. · 2021 [cited by applicant]
US 11229705B2 · Pottier et al. · 2022 [cited by applicant]
US 11247054B2 · Levy et al. · 2022 [cited by applicant]
US 11278723B2 · Meyre et al. · 2022 [cited by applicant]
US 11304902B2 · Pottier et al. · 2022 [cited by applicant]
US 11357724B2 · Pottier et al. · 2022 [cited by applicant]
US 11471410B2 · Germain et al. · 2022 [cited by applicant]
US 11471482B2 · Pottier et al. · 2022 [cited by applicant]
US 11497717B2 · Meyre et al. · 2022 [cited by applicant]
US 11819548B2 · Borghi et al. · 2023 [cited by applicant]
US 20020061298A1 · Coffey et al. · 2002 [cited by applicant]
US 20020177583A1 · Kiss · 2002 [cited by applicant]
US 20080171982A1 · Mehier · 2008 [cited by applicant]
US 20100040555A1 · Levy et al. · 2010 [cited by applicant]
US 20100320402A1 · Wu et al. · 2010 [cited by applicant]
US 20110213192A1 · Levy et al. · 2011 [cited by applicant]
US 20120203050A1 · Levy et al. · 2012 [cited by applicant]
US 20140335015A1 · Pottier et al. · 2014 [cited by applicant]
US 20160136304A1 · Poul et al. · 2016 [cited by applicant]
US 20170258718A1 · Meyre et al. · 2017 [cited by applicant]
US 20170258937A1 · Meyre et al. · 2017 [cited by applicant]
US 20190314530A1 · Poul et al. · 2019 [cited by applicant]
US 20210353670A1 · Marill et al. · 2021 [cited by applicant]
US 20220212008A1 · Meyre et al. · 2022 [cited by applicant]
US 20230211175A1 · Borghi et al. · 2023 [cited by applicant]
WO WO2009147214 · 2009 [cited by applicant]
WO WO2011003999 · 2011 [cited by applicant]
WO WO2011127061 · 2011 [cited by applicant]
WO WO2013087920 · 2013 [cited by applicant]
Herrera, A., et al., “Breakthrough concept in local treatment for advanced tumors,” NTBX Chicago, Jun. 3, 2013, pp. 1-51. [cited by applicant]
Maggiorella, L., et al., “Nanoscale radiotherapy with hafnium oxide nanoparticles,” [cited by applicant]
Nanobiotix, “Release / Nanobiotix Starts Clinical Trial with Lead Product NBTXR3,” Sep. 13, 2011, XP002671267, p. 1, retrieved from internet: URL:http://www. nanobiotix.com/news/release/nanobiotix-starts-clinic-trial-wi… [cited by applicant]
Pottier, A., et al., “New Use of Metals as Nanosized Radioenhancers,” [cited by applicant]
Written Opinion in International Application No. PCT/EP2014/051367, May 20, 2014, pp. 1-8. [cited by applicant]
Miller, T. R. et al. “Measurement of Tumor Volume By Pet To Evaluate Prognosis in Patients With Advanced Cervical Cancer Treated By Radiation Therapy” [cited by applicant]
Bush, D. A. et al. “Proton-Beam Radiotherapy for Early-Stage Lung Cancer” Chest, Nov. 1999, pp. 1313-1319, vol. 116, No. 5. [cited by applicant]
Claims as filed in U.S. Appl. No. 18/035,303, filed May 4, 2023, pp. 1-3. [cited by applicant]
Claims as filed in U.S. Appl. No. 18/039,728, filed Jun. 1, 2023, pp. 1-3. [cited by applicant]